Towards effective adjuvant treatment for urothelial cancer
Mené sur 284 patients atteints d'un carcinome urothélial de la vessie de stade pT3-pT4 ou N+ M0, cet essai randomisé international de phase III évalue l'efficacité, du point de vue de la survie globale, d'une chimiothérapie adjuvante administrée immédiatement après une cystectomie radicale ou après l'observation d'une récidive
Data for the efficacy of adjuvant chemotherapy in urothelial cancer comes from prematurely closed trials with poor accrual that have not yielded definitive conclusions about benefit. Yet, the potential activity reported in these trials has been promising enough to encourage investigators to pursue assessment of this treatment. In The Lancet Oncology, Cora Sternberg and colleagues report the results of the EORTC 30994 trial, which compared immediate versus deferred cisplatin-based combination chemotherapy after radical cystectomy in patients with urothelial carcinoma of the bladder